8-K: Passage Bio Updates FTD Trial Data, Explores Strategic Alternatives

Passage Bio announced updated interim data from its PBFT02 trial for FTD-GRN, showing reduced brain atrophy and stabilized NfL, but faces FDA requirement for a randomized trial, prompting a strategic review.

Summary

• Passage Bio released updated interim data from the Phase 1/2 upliFT-D clinical trial for PBFT02, a treatment for frontotemporal dementia caused by progranulin deficiency (FTD-GRN).
• Patients with a baseline CDR score of 1 showed a 64% reduction in whole brain atrophy and a 54% reduction in frontotemporal cortex atrophy at 12 months compared to natural history data.
• Plasma neurofilament (NfL) levels stabilized at 12 months post-treatment in PBFT02-treated patients, contrasting with an increase in untreated patients.
• Cerebrospinal fluid (CSF) progranulin (PGRN) levels showed robust and durable increases through 18 months with Dose 1 PBFT02, and Dose 2 achieved comparable levels by six months.
• The FDA indicated that a randomized controlled registrational study design is required for PBFT02 in this indication.
• Due to the challenges of a randomized trial, Passage Bio has initiated a review of strategic alternatives to maximize shareholder value, engaging Wedbush PacGrow as a financial advisor.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed signal; while the clinical data shows positive trends and biomarker improvements, the FDA's requirement for a randomized trial and the subsequent strategic review introduce significant uncertainty and potential challenges for the company's future development path and shareholder value.

Positives

• PBFT02 treatment demonstrated a significant reduction in brain atrophy (64% whole brain, 54% frontotemporal cortex) at 12 months in FTD-GRN patients with a baseline CDR score of 1, compared to natural history data.
• Plasma NfL levels stabilized in treated patients, a positive biomarker trend compared to the increase seen in natural history data.
• Durable and robust increases in CSF progranulin (PGRN) levels were observed through 18 months with Dose 1 PBFT02, and Dose 2 showed comparable levels by six months.
• PBFT02 was generally well-tolerated, with no new treatment-related serious adverse events reported since the previous update.
• No evidence of dorsal root ganglion toxicity or complications from intra-cisterna magna administration were reported.

Negatives

• The FDA requires a randomized controlled registrational study design for PBFT02 in FTD-GRN, posing significant ethical, logistical, and financial challenges.
• Patients with more advanced disease progression (global CDR score of 2 at baseline) showed no improvements in brain atrophy measures compared to natural history data.
• Two patients who received Dose 1 PBFT02 experienced asymptomatic serious adverse events: venous sinus thrombosis (n=2) and hepatotoxicity (n=1).

Risks

• Uncertainties inherent in the strategic review process, including the possibility that no suitable strategic alternative will be identified or consummated.
• The requirement for a randomized controlled registrational trial for PBFT02 presents substantial ethical, logistical, and financial challenges.
• The risk that positive results in early-stage clinical trials may not be replicated in subsequent trials or that success in early trials may not predict success in later-stage trials.
• Potential for unexpected concerns to arise from additional data or analysis during clinical trials.
• Regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of drug candidates.
• The occurrence of adverse safety events.
• Failure to protect and enforce intellectual property and other proprietary rights.
• Dependence on collaborators and third parties for development and manufacturing.

Future Outlook

The company is evaluating potential next steps for the PBFT02 clinical development program and for the company, including a review of strategic alternatives. There is no assurance that the strategic review process will result in any specific transaction.

Management Comments

• "the data shared today suggest that PBFT02 may slow neurodegeneration in patients with FTD-GRN, with improvements observed in both brain atrophy and plasma neurofilament levels, two well-established biomarkers of disease progression."
• "Further, we continue to observe durable and robust elevations in progranulin, the target protein, and are encouraged by the emerging data from Dose 2 patients, which indicate that this lower dose level can achieve similar progranulin expression as observed with Dose 1, our higher dose."
• "As we look towards late-stage development of the program, we recently completed a Type C meeting with the FDA to gain feedback on the design of a future registrational trial for PBFT02 in FTD-GRN."
• "Despite the rare, underserved nature of this devastating disease and the availability of robust natural history data, FDA did not support a single-arm trial design for this indication and instead indicated that a randomized controlled trial would be required for registrational purposes."
• "In light of this outcome and the associated ethical, logistical, and financial challenges, we are currently evaluating potential next steps for the PBFT02 clinical development program and for the company."

Industry Context

StockSavvy.ai notes that the FDA's requirement for a randomized controlled trial for PBFT02 in FTD-GRN, despite promising biomarker data, highlights the stringent regulatory pathway for novel gene therapies, particularly in rare neurological diseases. This also underscores the increasing complexity and cost associated with late-stage clinical development, often necessitating strategic reviews for companies of Passage Bio's size.

Comparison to Industry Standards

• The observed 64% reduction in whole brain atrophy and 54% reduction in frontotemporal cortex atrophy at 12 months for CDR 1 patients treated with PBFT02 compares favorably to natural history data from the ALLFTD consortium, which serves as a benchmark for FTD-GRN progression.
• The stabilization of plasma NfL levels in PBFT02-treated patients contrasts with the average increase of 13.5 pg/mL seen in untreated FTD-GRN patients from the ALLFTD natural history data, indicating a potential disease-modifying effect.
• The durable increase in CSF progranulin (PGRN) levels to a mean of 22.8 ng/mL at 12 months (Dose 1) and comparable levels with Dose 2 by six months exceeds the upper limit of the healthy adult reference range (3.28-8.15 ng/mL), demonstrating robust target engagement.

Stakeholder Impact

• Shareholders may face uncertainty due to the strategic review process and the potential for various transaction outcomes.
• Patients with FTD-GRN and their families face continued uncertainty regarding the development pathway and availability of PBFT02, given the FDA's requirement for a randomized trial and the company's evaluation of next steps.
• The company's employees may experience uncertainty regarding future operations and strategic direction as the review of alternatives progresses.

Next Steps

• Passage Bio is evaluating potential next steps in the clinical development of PBFT02 in FTD-GRN and FTD-C9orf72.
• The company is undertaking a review of strategic alternatives, which may include merger or acquisition transactions, a reverse merger, a sale of assets, strategic partnerships, or licensing opportunities.
• Wedbush PacGrow has been engaged as a financial advisor to assist in the strategic review process.

Key Dates

Recommendation

The company presents promising clinical data for PBFT02, demonstrating positive biomarker and atrophy trends. However, the FDA's requirement for a randomized controlled trial introduces significant development hurdles and costs. Coupled with the initiation of a strategic review process, this creates substantial uncertainty. A 'hold' recommendation is appropriate, pending clarity on the strategic alternatives and the feasibility of advancing the PBFT02 program under the new regulatory guidance.

Keywords

Passage Bio, PBFT02, FTD-GRN, Frontotemporal Dementia, Gene Therapy, Clinical Trial, FDA, Strategic Alternatives